Navigation Links
Akorn, Inc. Announces Second Quarter 2009 Earnings Release and Conference Call Information
Date:7/29/2009

LAKE FOREST, Ill., July 29 /PRNewswire-FirstCall/ -- Akorn, Inc. (Nasdaq: AKRX) will release second quarter 2009 earnings Monday, August 10 after stock market close. The company will host a conference call on Tuesday, August 11 to discuss quarterly results followed by a Q&A session:

    Subject:               Akorn Second Quarter 2009 Conference Call

    Date/Time:             Tuesday, August 11, 2009 at 10:00 a.m. Eastern Time

    Domestic Callers:      (800) 289-0479

    International Callers: (913) 981-5519

URL For Webcast: http://www.videonewswire.com/event.asp?id=56168

The live broadcast of Akorn's conference call will also be available online at www.akorn.com under the investor relations tab on August 11, 2009, beginning at 10:00 a.m. (Eastern Time). The online replay will follow immediately and will be available for 30 days.

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company's website at www.akorn.com.

This press release includes statements that may constitute "forward-looking statements", including with regard to the company's future operations and its earnings expectations. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. Factors that could cause or contribute to such differences include, but are not limited to: statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by the company or by persons acting on its behalf and in conjunction with its periodic SEC filings. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Other factors besides those listed there could also adversely affect our results


'/>"/>
SOURCE Akorn, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stryker Announces Election of New Director
2. Birdies for Breast Cancer Announces Fifth Annual Charity Golf Classic Hosted by Top Womens Golfer, Cristie Kerr
3. ASTRO announces 2009 Fellows
4. Smith & Nephew Announces Launch of ACTICOAT Flex Wound Care Products in the USA
5. Boston Scientific Announces Election of Katharine Bartlett and Bruce Byrnes to Its Board of Directors
6. Hillenbrand Announces Third-Quarter Earnings Release Date and Conference Call
7. Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
8. Patriot Scientific Corporation Announces Cardiac Science Corporations Purchase of a Moore Microprocessor Patent(TM) Portfolio License
9. QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy
10. Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009
11. HCA Announces Offering of $750 Million Senior Secured First Lien Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
(Date:12/5/2016)... Novato, CA (PRWEB) , ... December 05, 2016 ... ... company, has extended its partnership with leading global lifestyle design firm kathy ireland® ... , Worldwise® and kathy ireland® Worldwide entered into an exclusive licensing agreement three ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive Laboratories™ is one of ... to enhance production of nitric oxide (NO). , NitroGenesis Pro™ is made with ... twice as effectively and sustains NO blood levels twice as long as comparable ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... announced that the company will provide alerting technology to Central Illinois Health ... awarded $1.7 million in federal funds as the sole sub-recipient participating with ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... BSI and ... the United States and Canada for distribution of their natural fruits and beverage ... line is an exciting addition to our Life Sciences product portfolio,” said Steve ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec 5, 2016 Research ... Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease ... - Global Forecasts to 2021" report to their offering. ... , , ... USD 730.7 Million in 2021 from USD 574.8 Million in 2016, ...
(Date:12/5/2016)... According to a new market research report "Cartilage Repair/ Cartilage ... Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - Forecast ... USD 779.8 Million by 2021 from USD 414.6 Million in 2016, ... 2016 to 2021. Continue Reading ... ...
(Date:12/5/2016)... India , December 5, 2016 According to a ... Type and by Application - Global Opportunity Analysis and Industry Forecast, 2014 - ... is expected to reach $5,255 million by 2022, growing at a CAGR of ... with more than four-fifths share. Continue Reading ... ...
Breaking Medicine Technology: